A PYMNTS Company

US/India: US okays Sun-Ranbaxy pharmaceutical deal

By  |  February 1, 2015

Sun Pharmaceutical has won US approval to buy Ranbaxy Laboratories on condition that it sell its interest in a generic antibacterial medicine, the US Federal Trade Commission said on Friday.

In April last year, Sun Pharmaceutical had agreed to buy generic drug maker Ranbaxy from its owner Japan’s Daiichi Sankyo Co for $3.2 billion.

The Federal Trade Commission said it would allow the transaction if Ranbaxy sold its interests in generic minocycline tablets and capsules to generic maker Torrent Pharmaceuticals Ltd, which is also based in India.

According to this order, the drugs that Ranbaxy will have to divest include Terlipresslin, Rosuvastatin and Leuprorelin.

Sun Pharma will have to either divest its molecules or ask Ranbaxy to divest molecules held by it in other drug areas.

The FTC said the proposed acquisition would reduce the number of future suppliers in the markets for generic minocycline tablets.

 

Full Content: The Hindu

 

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.